Latest news with #Mackin
Yahoo
19-05-2025
- Business
- Yahoo
AORT Q1 Earnings Call: Early Product Launches and Supply Recovery Drive Outperformance
Medical device company Artivion (NYSE:AORT) reported Q1 CY2025 results beating Wall Street's revenue expectations , with sales up 1.6% year on year to $98.98 million. The company's full-year revenue guidance of $429 million at the midpoint came in 1.2% above analysts' estimates. Its non-GAAP profit of $0.06 per share was $0.02 above analysts' consensus estimates. Is now the time to buy AORT? Find out in our full research report (it's free). Revenue: $98.98 million vs analyst estimates of $94.98 million (1.6% year-on-year growth, 4.2% beat) Adjusted EPS: $0.06 vs analyst estimates of $0.05 ($0.02 beat) Adjusted EBITDA: $17.55 million vs analyst estimates of $16.47 million (17.7% margin, 6.6% beat) The company slightly lifted its revenue guidance for the full year to $429 million at the midpoint from $427.5 million Operating Margin: 2.2%, down from 26% in the same quarter last year Free Cash Flow was -$20.59 million compared to -$9.1 million in the same quarter last year Sales Volumes rose 10.8% year on year (14.2% in the same quarter last year) Market Capitalization: $1.26 billion Artivion's first quarter was shaped by the rapid recovery from a previously disclosed cybersecurity incident and the early momentum of key product launches. CEO Pat Mackin highlighted that supply chain stabilization, particularly for On-X mechanical valves, and clearance of about a third of the tissue processing backlog enabled the company to surpass internal expectations. Management also pointed to double-digit revenue gains in its stent graft and On-X product lines, partially offset by ongoing softness in preservation services due to lingering supply constraints. Looking ahead, management's guidance reflects confidence in accelerating revenue and margin growth, supported by the ongoing U.S. launch of the AMDS device and anticipated recovery in tissue processing volumes. Mackin emphasized the potential for sustained double-digit growth and noted that product mix improvements—especially with AMDS and favorable On-X data—are expected to drive higher gross margins. CFO Lance Berry added that management expects free cash flow to turn positive as the year progresses, with incremental contributions from backlog resolution and new product adoption. Artivion's leadership attributed the quarter's results to faster-than-expected operational normalization, new clinical launches, and growth in select product segments. Key factors driving financial performance and expectations for the rest of the year included: Cybersecurity Incident Recovery: The company made significant progress on restoring operations after the supply chain disruption, clearing a third of the tissue processing backlog ahead of schedule and returning On-X manufacturing to normal levels earlier than anticipated. Stent Graft Expansion: Stent graft revenue grew 19% in constant currency, driven by cross-selling in Europe and initial U.S. uptake of the AMDS device, which received FDA Humanitarian Device Exemption (HDE) approval. Management noted that most current stent graft sales are outside the U.S., but the pipeline aims to expand into new geographies, including the U.S. and Japan. AMDS U.S. Launch: Early feedback from surgeons and adoption by around 150 facilities underscored strong demand, though onboarding varies due to regulatory steps at each hospital. Management expects sequential sales growth for AMDS throughout the year. On-X Valve Performance: On-X revenue rose 11% year-over-year, aided by normalization of supply and favorable clinical data showing improved mortality for patients under 60 compared to bioprosthetic valves. Management cited this as opening a $100 million U.S. market opportunity. Geographic Growth Drivers: Latin America and Asia Pacific posted revenue increases of 26% and 8%, respectively, as regulatory approvals and expanded commercial presence supported growth. Management expects these regions to remain important contributors going forward. Management expects accelerating growth in coming quarters as new product rollouts and backlog resolution offset lingering headwinds. The company's outlook is anchored in continued product adoption and operational recovery. AMDS and NEXUS Pipeline: Broader adoption of AMDS in the U.S. and anticipated approval of the NEXUS stent graft system are viewed as major future growth drivers, with management highlighting their combined $250 million annual U.S. market potential. Tissue Processing Recovery: Full normalization of tissue processing volumes is expected by the end of Q3, which management believes will restore mid-single digit growth in this segment for the full year. Margin Expansion Initiatives: Management pointed to product mix improvements, especially from AMDS and On-X, and SG&A leverage as key levers for adjusted EBITDA margin expansion. Risks cited include the pace of hospital onboarding and the timing of regulatory approvals. John McAulay (Stifel): Asked about the pace of AMDS adoption and whether all 150 facilities could be live by year-end; management stated onboarding is progressing well but timing depends on each hospital's processes. Frank Takkinen (Lake Street Capital): Inquired about surgeon training and the true U.S. market size for AMDS; management reported training has exceeded expectations and the market could expand beyond current estimates if clinical outcomes remain favorable. Mike Matson (Needham & Company): Questioned the timing and financing of the potential Endospan (NEXUS) acquisition; management said the option triggers upon FDA approval, with financing seen as manageable through improved EBITDA and cash flow. Daniel Stauder (Citizens JMP): Sought clarity on foreign exchange headwinds in guidance; management said currency impacts are now expected to be neutral for the year, with constant currency growth emphasized in projections. Jeffrey Cohen (Ladenburg Thalmann): Asked about APAC and Latin America contributions; management cited ongoing product approvals and commercial expansion as sustaining strong growth in both regions. In future quarters, the StockStory team will be watching (1) the pace at which AMDS gains hospital approvals and drives sequential revenue, (2) the resolution of the tissue processing backlog and resulting return to mid-single digit growth in that segment, and (3) continued progress toward U.S. approval for the NEXUS stent graft system. Execution against these milestones will be key for sustained double-digit growth and margin improvement. Artivion currently trades at a forward P/E ratio of 43.9×. In the wake of earnings, is it a buy or sell? See for yourself in our free research report. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Sunday World
13-05-2025
- Sunday World
‘Gentle' grandmother killed after being struck by car named locally
The pensioner, who was aged in her 70s, has been named locally as Nora Mackin A 'gentle' grandmother who died following a single vehicle crash in Co Armagh has been named locally as Nora Mackin. The pensioner, who was aged in her 70s, was struck by a car in the Tullynavall Road area of Cullyhanna on Monday. A death notice remembers Mrs Mackin as the 'loving wife of Stephen. Devoted mother to Martin, Maureen (Larkin), Fiona (Sims) and Kevin' and a grandmother of seven. She also had four siblings. "Deeply regretted by her husband, sons, daughters, grandchildren, sons-in-law Peter and Nigel, daughter-in-law Paula, brother, sisters and extended family,' the death notice states. Funeral arrangements have not yet been confirmed. Councillors in the area have offered condolences to the bereaved family. Cullyhanna woman, Nora Mackin Sharing his sympathy, UUP representative, David Taylor said: 'I am very sorry to hear of this tragic accident that occurred'. 'I sincerely want to extent my sympathies to the family.' Sinn Fein representative Martin Hearty also offered condolences. 'Obviously this is a tragic situation. Our thoughts are with the family at this time,' he said. Emergency services – including fire crews and the air ambulance – attended the scene of the collision on May 13. Despite frantic efforts to save Mrs Mackin, she was pronounced dead at the scene. Police have appealed to anyone who may have witnessed the incident or anyone with CCTV or other footage that can help with enquiries to contact detectives on 101 quoting reference 301 12/0525. Alternatively witnesses can make a report on the PSNI's online reporting form. Many people have paid tributes to Mrs Mackin on social media. "Armagh City & District Lourdes Committee offer our sincere condolences to Stephen and the entire family circle on the tragic loss of Nora a gentle lovely lady,' one user wrote. Cullyhanna woman, Nora Mackin News in 90 Seconds - May 13th Another posted: 'She was an angel and we are forever indebted to her for everything she did to help our family over the last few years. She will be missed. May her gentle soul rest in peace.' A third person said: 'So so sad and difficult to take in. May Nora Rest in Peace and sincere condolences to all the family, praying for some comfort for you all.' Many other Facebook users sent messages of support to the family following the loss of 'such a lovely gentle lady'.
Belfast Telegraph
07-05-2025
- Sport
- Belfast Telegraph
How four members of the Mackin family will be eyeing double Ulster Final delight for Armagh
This Saturday the Mackin household will have four siblings featuring in an Ulster Final at Clones, as both the Armagh men and ladies' teams go up against their Donegal counterparts in a highly-anticipated double-header. Blaithin Mackin is normally preparing for games alongside her sister Aimee, but the latter is ruled out with injury and so helps the team in any other way that she can, while their two brothers Connaire and Ciaran will be lining out for Kieran McGeeney's squad in the second game of the day.
BBC News
17-04-2025
- BBC News
Andy Burnham backs Summerland families' 'search for answers'
The mayor of Greater Manchester has backed a formal application for a fresh inquest into the deaths of 50 people killed in the 1973 Summerland disaster on the Isle of Burnham shared his support for the Justice for Summerland Group, made up of survivors and relatives of victims. The group is calling for the island's Attorney General to reopen the case, which originally recorded a verdict of misadventure. Burnham said: "If they're still fighting it means things were not done properly at the time and they didn't get the answers that they deserved." About 3,000 people were at the Summerland entertainment complex in Douglas when a fire broke out on the evening of 2 August was believed the blaze was started by three boys from Liverpool smoking. 'Left in the wilderness' Lending his support, Burnham said: "I know from my experience from working with the Hillsborough families, families are often left in the wilderness."It's too easy in this country to cover up, it's too hard for families to get to the truth."I know if they're still fighting it means things were not done properly at the time and they didn't get the answers that they deserved," he added.A public inquiry held in the aftermath of the Summerland disaster found there were "no villains" and only human beings who made for Summerland has appointed Belfast-based human rights law firm Phoenix Law to act for the Mackin from the legal firm last year represented many families of 48 young people killed in the Stardust fire in Dublin in 1981, who successfully fought for their own fresh inquest. Read more stories from the Isle of Man on the BBC, watch BBC North West Tonight on BBC iPlayer and follow BBC Isle of Man on Facebook and X.
Miami Herald
17-03-2025
- Miami Herald
Man tags Florida homes with antisemitic graffiti, then flees to Northern Ireland, cops say
A 71-year-old man accused of spray painting antisemitic graffiti on Florida homes and businesses was arrested in Northern Ireland on an Interpol warrant, deputies said. Liam Mackin lived in Flagler Beach but left the country after officers obtained an arrest warrant for him in connection with the vandalism, according to a Flagler County Sheriff's Office news release. 'Mackin's actions incited fear within our community,' Sheriff Rick Staly said in the March 14 release. 'There are no borders when it comes to stopping criminals from terrorizing our community.' According to deputies, Mackin was seen on security cameras in November 2023 tagging a total of six businesses and homes with 'prejudicial hate graffiti targeting the Jewish community.' Mackin was charged with criminal mischief ($1,000 or more) – evidencing prejudice while committing an offense, but authorities said they believed he was hiding abroad. Northern Ireland authorities told the Flagler County Sheriff's Office that he had been arrested on March 14, deputies said. He is being extradited back to Flagler County, which could take up to six months, according to deputies. 'Mackin thought fleeing to Ireland would prevent him from prosecution; he thought wrong,' Flagler Beach Police Chief Matt Doughney said.
